Diabetic dyslipidemia

Endocrinol Metab Clin North Am. 2006 Sep;35(3):491-510, vii-viii. doi: 10.1016/j.ecl.2006.06.002.

Abstract

Type 2 diabetes mellitus is associated with a markedly increased risk of cardiovascular disease. A complex dyslipidemia, which is an integral part of the underlying insulin resistance in this group, is a key to this increased risk. Increased secretion of VLDL from the liver is a central feature of dyslipidemia and is linked significantly to the low HDL and abnormal LDL that are also present. A number of physiologic and pharmacologic approaches are available and should be used aggressively to treat diabetic dyslipidemia.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / prevention & control
  • Chylomicrons / metabolism
  • Diabetes Complications*
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Humans
  • Hyperlipidemias / complications*
  • Lipoproteins / metabolism
  • Lipoproteins, HDL / metabolism
  • Lipoproteins, HDL / physiology
  • Lipoproteins, LDL / blood
  • Lipoproteins, LDL / metabolism
  • Lipoproteins, VLDL / biosynthesis
  • Lipoproteins, VLDL / metabolism
  • Liver / metabolism
  • Particle Size
  • Risk Factors

Substances

  • Chylomicrons
  • Lipoproteins
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Lipoproteins, VLDL